Search
Quince Therapeutics Inc
QNCXAdd to Watchlist
34.040USD
+1.630+5.03%
Close 08-14 16:00（ET）Quotes delayed by 15 min
34.62MMarket Cap
1.50P/E TTM
More Details of Quince Therapeutics Inc Company
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Quince Therapeutics Inc Profile
Ticker SymbolQNCX
Company nameQuince Therapeutics Inc
IPO dateMay 09, 2019
CEOThye (Dirk)
Number of employees36
Security typeOrdinary Share
Fiscal year-endMay 09
Address601 Gateway Boulevard, Suite 1250
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone14159105717
Websitehttps://quincetx.com/
Ticker SymbolQNCX
IPO dateMay 09, 2019
CEOThye (Dirk)
Company Executives of Quince Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
497.00
-173.04%
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
497.00
-173.04%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
181.00
-921.55%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
181.00
-921.55%
Dr. Luca Benatti, Ph.D.
Dr. Luca Benatti, Ph.D.
Independent Director
Independent Director
151.00
-165.56%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
65.00
-900.00%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
65.00
-900.00%
Mr. David A. Lamond, J.D.
Mr. David A. Lamond, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Margaret A. Mcloughlin, Ph.D.
Dr. Margaret A. Mcloughlin, Ph.D.
Independent Director
Independent Director
--
--
Dr. Una Ryan, OBE
Dr. Una Ryan, OBE
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
497.00
-173.04%
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
497.00
-173.04%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
181.00
-921.55%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
181.00
-921.55%
Dr. Luca Benatti, Ph.D.
Dr. Luca Benatti, Ph.D.
Independent Director
Independent Director
151.00
-165.56%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
65.00
-900.00%
FAQs
Who are the top five shareholders of Quince Therapeutics Inc?
The top five shareholders of Quince Therapeutics Inc are: Dr. Dirk Thye, M.D.
How many institutions hold shares of Quince Therapeutics Inc (QNCX)?
As of 2026Q1, 113 institutions hold shares of Quince Therapeutics Inc, with a combined market value of approximately 2.11M, accounting for 12.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 339720.00.